Help appealing denials for this first menin inhibitor for relapsed/refractory AML.

Appeal Your Komzifti Denial

Get access to this targeted therapy for NPM1-mutated acute myeloid leukemia.

Start Your Appeal
Chat with AI Assistant

Understanding Your Komzifti (ziftomenib) Denial

Komzifti (ziftomenib) is the first and only menin inhibitor approved for adults with relapsed or refractory acute myeloid leukemia (AML) with NPM1 mutation who have no satisfactory alternative treatment options. This oral medication targets a key driver of NPM1-mutated AML. Insurance denials often require proof of NPM1 mutation testing and prior treatment failure.

Common Reasons for Denial

  • ! NPM1 mutation not documented by approved test
  • ! Prior authorization required
  • ! Prior therapies not adequately documented
  • ! No satisfactory alternatives not established
  • ! Specialty tier drug not covered
  • ! Off-label use concerns

How We Help

We help you compile your NPM1 mutation testing results, prior treatment history, and oncologist recommendations to demonstrate that you have no satisfactory alternative treatment options.

Start your Komzifti appeal — it takes about 3 minutes.

Some Types of Evidence We Can Use For Supporting Your Appeal

✓ Ziftomenib is a menin inhibitor that blocks the interaction between menin and MLL proteins, disrupting leukemia cell growth in NPM1-mutated AML.

✓ NPM1 mutations occur in approximately 30% of AML patients and represent a distinct molecular subtype.

✓ Clinical trials demonstrated meaningful response rates in heavily pretreated patients with relapsed/refractory NPM1-mutated AML.

✓ Oral targeted therapy offers improved quality of life compared to intensive chemotherapy regimens.

Financial Assistance Directory

Curated copay foundations, manufacturer programs, and safety-net clinics that may help with the cost while you appeal.

For your condition

CancerCare Co-Payment Assistance Foundation

Copay assistance for chemotherapy and targeted therapies for specific cancer diagnoses. Funds open/close by cancer type.

Leukemia & Lymphoma Society Co-Pay Assistance

Copay, insurance premium, and travel assistance for patients with blood cancers (leukemia, lymphoma, myeloma, MDS).

General copay foundations & directories

NeedyMeds

Searchable database of 5,000+ patient assistance, copay, and diagnosis-specific programs. Start here if you are not sure where to look.

Eligibility: No eligibility check - the directory itself is free. Individual programs have their own income and insurance criteria.

Patient Advocate Foundation Co-Pay Relief

Direct copay assistance for insured patients with chronic, life-threatening, or rare conditions. Covers many disease funds.

Eligibility: Generally requires insurance coverage and income up to 400% of the federal poverty level (varies by fund).

Phone: 1-866-512-3861

HealthWell Foundation

Independent charity providing copay, premium, and travel assistance grants across 70+ disease funds.

Eligibility: Must have insurance covering the prescribed treatment; income thresholds vary by fund. Funds open and close as donations allow.

The Assistance Fund (TAF)

Copay, insurance premium, and travel assistance for patients with chronic and rare diseases.

Eligibility: Must have insurance and meet income limits (typically up to 500% FPL, fund-dependent).

Good Days

Copay assistance and other support for chronic-disease patients.

Eligibility: Funds vary by disease and open/close based on availability. Usually requires insurance and income under ~500% FPL.

PAN Foundation (Patient Access Network)

Disease-specific copay assistance funds for ~70 conditions. Funds open and close throughout the year - check the website or sign up for fund-open alerts.

Eligibility: Insurance required; income limits typically 400-500% of FPL depending on the fund.

NORD (National Organization for Rare Disorders)

Patient assistance, copay, and travel programs for people living with rare diseases.

RxAssist Patient Assistance Program Center

Comprehensive directory of manufacturer patient assistance programs. Search by medication to find the manufacturer's free-drug program if you are uninsured or under-insured.

Safety-net clinics & 340B

HRSA Find a Health Center (FQHC locator)

Federally Qualified Health Centers (FQHCs) provide primary care on a sliding-fee scale and dispense many medications at 340B-discounted prices, regardless of insurance status. Often the cheapest path for uninsured or under-insured patients.

HRSA 340B Program (provider directory + program info)

Background on the 340B Drug Pricing Program. Use to verify whether a particular clinic or hospital is a covered entity before assuming discounted pricing applies.

State Pharmaceutical Assistance Program (SPAP) directory

State-run programs (mostly for seniors and people with disabilities) that supplement Medicare Part D and reduce prescription costs. Availability and benefits vary by state.

Medicaid eligibility & application (Healthcare.gov)

If denied insurance is unaffordable, check Medicaid / CHIP eligibility - thresholds and pathways vary by state, and many expansion states cover adults up to 138% FPL.

Program eligibility, fund availability, and contact info change frequently. Verify with each organization before assuming a program is open.

Patient Advocacy & Support Organizations

These organizations provide education, support, and advocacy for patients:

Leukemia & Lymphoma Society ↗

World's largest voluntary health agency dedicated to blood cancer research and patient support.

International Myeloma Foundation ↗

Largest organization focusing specifically on multiple myeloma research and patient education.

Frequently Asked Questions

You need documentation of a susceptible NPM1 mutation detected by an FDA-approved companion diagnostic or validated molecular testing. Your oncologist should have ordered this testing as part of your AML workup.

This means you've tried other available AML treatments or they are not appropriate for you due to your specific situation, comorbidities, or disease characteristics. Your oncologist should document why Komzifti is the best option.

Ready to Fight Your Komzifti (ziftomenib) Denial?

Our free AI-powered tool will help you generate a compelling appeal letter in minutes.

Start Your Appeal Chat with AI Assistant

Disclaimer: Fight Health Insurance is not affiliated with, endorsed by, or partnered with any pharmaceutical manufacturer, healthcare provider, medical device company, or patient assistance program, including Kura Oncology / Kyowa Kirin. All information provided is for educational and informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider regarding treatment options and with your insurance company regarding coverage decisions.